Commentary

DPP-4 inhibitors in the treatment of type 2 diabetes

Hélène Duez [a,b,c,d], Bertrand Cariou [e,f,g], Bart Staels [a,b,c,d,*]

[a] Univ Lille Nord de France, F-59000 Lille, France
[b] Inserm, U1011, F-59000 Lille, France
[c] UDSL, F-59000 Lille, France
[d] Institut Pasteur de Lille, F-59019 Lille, France
[e] Inserm, U915, Nantes, France
[f] Clinique d'Endocrinologie, L'Institut du Thorax, CHU Nantes, Nantes, France
[g] Université de Nantes, Faculté de Médecine, Nantes, France

ABSTRACT

Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a $\geq$80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.

© 2011 Elsevier Inc. All rights reserved.

1. Introduction

Diabetes mellitus is recognized as a major health problem affecting millions of people and predisposing to micro- and macro-vascular complications including coronary heart disease. A tight glycaemic control reduces the morbidity and mortality associated to type 2 diabetes [1,2], but has proven challenging and is usually not sustained. The currently used anti-diabetic drugs show a loss of efficacy over time [3], a poor tolerability and low compliance due to numerous adverse effects, including severe hypoglycaemia, weight gain, oedema, nausea and gastrointestinal derangements. Thus, new strategies were needed that allow a sustained glycaemic control and avoid hypoglycaemia and other side effects.

After food ingestion, specialized neuroendocrine cells of the gastro-intestinal tract release peptides which act to improve glucose handling and energy homeostasis. Among these gut hormones are the incretins glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic peptide (GIP) which increase meal-stimulated insulin release by the pancreas, suppress gluca-gon secretion and improve glucose disposal. Recent advances in the understanding of the physiological functions of incretins have led to the emergence of a new class of oral anti-diabetic drugs which, by inhibiting the dipeptidyl peptidase (DPP)-4 enzyme, result in increased concentrations of the endogenous incretins GLP-1 and GIP, and consequently improve fasting and post-prandial hyperglycaemia. Several DPP-4 inhibitors have been developed, with five already approved in the USA, Europe and/or Japan (sitagliptin, vildagliptin, saxagliptin, alogliptin and linaglip-tin). These inhibitors display different chemical structures and pharmacodynamic/pharmacokinetic properties, but all are effica-cious for managing diabetes and generally well-tolerated. They allow a reduction in HbA1c levels by 0.5–1%, and have other beneficial actions on pancreatic β-cell function, blood pressure and lipid levels for instance.

1.1. The 'incretin effect': physiological basis

The term 'incretin effect' has been coined to describe stimulated insulin secretion after oral glucose ingestion compared to

* Corresponding author at: UMR1011, Institut Pasteur de Lille, 1 rue du professeur Calmette, BP245, F-59019 LILLE, France. Tel.: +33 3 20 877388; fax: +33 3 2087 7360.
E-mail address: bart.staels@pasteur-lille.fr (B. Staels).

isoglycaemic parenteral or iv glucose administration [4]. Several peptides released by the intestine into the circulation in a nutrient-dependent manner account for this potentiation of post-prandial insulin release by the pancreas, and act as triggering signals for the control of appetite, intestinal nutrient absorption and ultimately in the maintenance of energy homeostasis [5]. GIP, for instance, is synthesized and released by entero-endocrine K cells present in the duodenum in response to nutrient (glucose or fat) ingestion and enhances glucose-stimulated insulin secretion [6,7]. The other incretin hormone GLP-1 derives from a pro-glucagon precursor peptide that gives rise also to GLP-2, oxyntomodulin and glicentin [8]. GLP-1 is secreted by L-cells mainly of the distal small intestine (ileum) and colon. Infusion of GLP-1 in the fasted state to mimic its post-prandial concentration increases insulin biosynthesis and release, and diminishes blood glucose [9,10]. Plasma levels of both peptides are low in the fasted state, rise within minutes after food ingestion and contribute to lower blood glucose by exerting potent glucose-dependent insulin stimulatory actions [7]. Indeed, GLP-1 and GIP stimulate β-cell insulin secretion [11,12]. In addition, the two incretins regulate pancreatic islet neogenesis, proliferation and survival in vitro [13] (Fig. 1).

Beside its insulinotropic effect, GLP-1 inhibits glucagon secretion by the pancreatic α-cells [14], resulting in a further decrease of hepatic glucose production in the post-prandial state in subjects treated with GLP-1-receptor agonists or DPP-4 inhibitors. GLP-1 also potentiates glucose disposal. Moreover, GLP-1 reduces food intake and gastric emptying through either direct effects on the gastrointestinal tract or indirect actions via the central nervous system [13], promoting satiety and improving weight maintenance. It is worth noting that, in humans, these effects are observed at supraphysiological concentrations, i.e. only after administration of GLP-1 analogs. In addition, GLP-1 inhibits intestinal lipoprotein secretion and may lower post-prandial hyperlipidaemia, which is a cardiovascular risk factor. Finally, GLP-1 exerts potentially beneficial vascular and cardio-protective actions (see below). In support of the gluco-regulatory and insulin stimulatory actions of GLP-1, GLP-1 receptor-deficient mice display altered glucose tolerance and diminished glucose-stimulated insulin secretion,

abnormal pancreatic islet number and size, but exhibit normal insulin sensitivity and glucagon secretion [15].

As mentioned above, GIP promotes insulin secretion in response to glucose. However, it does not inhibit glucagon secretion nor does it modulate gastric emptying [13]. In addition, GIP increases fatty acid uptake and lipogenesis by adipocytes [16,17], promoting fat deposition. Accordingly, GIP-receptor-deficient mice have defective insulin secretion in response to oral glucose [18], but resist to the development of diet- or genetically induced obesity and have improved insulin sensitivity [19]. GLP-1-receptor and GIP-receptor double knock-out mice are glucose intolerant as shown by the abnormal glucose excursion in oral glucose tolerance tests, and significantly lower glucose-stimulated insulin secretion [20].

Several reports suggest that the incretin effect is reduced in type 2 diabetic patients [21] [22], although recent studies indicate that the reduction of insulin secretion is primarily due to an impairment in β-cell function after chronic hyperglycaemia rather than a primary defect in glucose-dependent GLP-1 and GIP action [23]. Defective post-prandial GLP-1 secretion in a mixed meal test has been observed in subjects with impaired glucose tolerance, albeit to a lesser extent compared to diabetic patients [22,24,25], although conflicting data have also been published [26]. In addition, the incretin effect and post-prandial GLP-1 response are reduced with increasing obesity [27,28]. However, although its secretion is altered, GLP-1 action is mostly preserved in type 2 diabetic patients, fostering pharmaceutical efforts aimed to potentiate or prolong GLP-1 action. Unlike GLP-1, circulating levels of GIP are not diminished in type 2 diabetic patients [22], and GIP has reduced insulinotropic actions in type 2 diabetes, which contributes to the reduced incretin effect in diabetics thus making it a much less attractive therapeutic target.

GLP-1 is secreted as GLP-1(7-36)-amide, the major circulating GLP-1 form, and GLP-1(7-37). It is released within minutes of food ingestion and displays a short half-life (∼1–2 min) [29] because of its rapid degradation through the action of DPP-4 and its renal clearance. Only 25% of the secreted GLP-1 reaches the portal vein, and only 10–15% the general circulation (Fig. 2). The half-life of


Fig. 1. Physiological actions of GLP-1 in different organs/tissues. Upon meal ingestion, GLP-1 is secreted by the intestine. GLP-1 enhances glucose-stimulated insulin secretion (incretin effect), diminishes glucagon production and hepatic glucose production, and increases pancreatic β-cell proliferation and survival. Additional actions have been described including gastric emptying, reduction of appetite and cardioprotective actions, among others.

Fig. 2. GLP-1 is rapidly degraded by dipeptidyl-peptidase (DPP-4). GLP-1 has a short half-life (1–2 min) because of rapid proteolytic degradation by DPP-4 (and renal elimination). DPP-4 inhibitors thus increase its half-life which results in prolongation of its biological actions.

administered GIP is 5 and 7 min in diabetic and non-diabetic subjects, respectively [30]. To counteract this rapid cleavage of native GLP-1 (and GIP), two therapeutic approaches have been developed: GLP-1 mimetics resistant to the degradation by DPP-4 and inhibitors of DPP-4 (or gliptins).

1.2. Physiological and preclinical studies to support the use of DPP-4 inhibitors in the control of glucose homeostasis

DPP-4 exists as a cell surface membrane-bound peptidase which is expressed in many tissues including the gastro-intestinal tract, liver, kidney, the vascular epithelium and the exocrine pancreas, and conveys intracellular signals to transduction pathways. DPP-4 also exists and exerts enzymatic activity in the plasma where it preferentially cleaves peptides with a proline or an alanine in position 2 of the N-terminus of the peptide. Hence, both GLP-1 and GIP, among others, are endogenous substrates for DPP-4. DPP-4 inhibition (by gliptins) or deletion studies in animal models have shed light on the role of this enzyme in glucose control. DPP-4-deficient mice show improved glucose tolerance, higher plasma GLP-1, GIP and insulin levels following an oral glucose gavage, reduced food intake and increased energy expenditure; they are resistant to diet-induced obesity and insulin resistance and to streptozotocin-induced diabetes [31,32]. Consistently, DPP-4 inhibition improved glucose tolerance, diminished hyperglycaemia and increased insulin secretion in diabetic Zucker rats [33–35] and increased hepatic and peripheral insulin sensitivity [36]. In vitro, vildagliptin-mediated DPP-4 inhibition increased insulin secretion by pancreatic islet cells [37]. Consistently, vildagliptin administration led to decreased weight gain and food intake, increased insulin levels and increased β-cell mass in carbohydrate-fed rats [38]. Sitagliptin treatment in vivo improved glucose homeostasis and pancreatic β-cell survival in diabetic streptozotocin-treated mice [39]. Sitagliptin has also been shown to increase β-cell number and insulin content [40,41]. Treatment with a sitagliptin analog (des-fluoro-sitagliptin) of diabetic ICR mice significantly reduced HbA1c and glucose levels, and decreased liver lipid accumulation while increasing pancreatic insulin content and enhancing glucose-stimulated insulin secretion [42].

In vitro, many other peptides are degraded by DPP-4 including GLP-2, growth-hormone-releasing hormone, pituitary adenylate cyclase activating polypeptide (PACAP) [43]. However, the hypoglycaemic action of DPP-4 inhibitors has been attributed mainly to increased GLP-1 and GIP levels. Indeed, administration of LAF237 (later renamed vildagliptin) or valine-pyrrolidide to inhibit DPP-4 activity led to a reduction of fasting glucose levels and ameliorated glucose tolerance in wild-type, but not in GLP-1-receptor and GIP-receptor double mutant mice, suggesting that both GLP1 and GIP signalling are necessary to the hypoglycaemic action of DPP-4 inhibitors [20]. In addition, administration of LAF237 to high-fat diet-fed mice improved glycaemic control in wild-type, but not GLP-1R and GIPR double mutant mice [44].

1.3. Pharmacodynamic and pharmacokinetic properties of the different DPP-4 inhibitors

As mentioned above, several inhibitors are on the market or in trials (Table 1). They are all orally available and well absorbed (i.e. significant DPP-4 inhibition is observed as soon as 15 min after administration), and have high affinity for DPP-4. They all potently inhibit plasma DPP-4 to similar levels, but with different IC50 (i.e. the concentration needed to achieve 50% of inhibition) ranging from 1 nM for linagliptin, 19 and 24 nM for sitagliptin and alogliptin, to 50 and 62 nM for saxagliptin and vildagliptin, respectively. Their half-life also is different, leading to different dosing amount and frequency as outlined below.

Sitagliptin is well absorbed (∼87%), and potently and selectively inhibits DPP-4. Its pharmacokinetic and pharmacodynamic properties have been determined in randomized, double-blind, placebo-controlled studies with single oral doses (1.5–600 mg) in healthy subjects [45]. Sitagliptin has an apparent terminal half-life ranging from 8 to 14 h. Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-4 activity, with $\geq$80% inhibition over the entire 24-h period at 100 mg. PK–PD relationships using multiple oral doses of sitagliptin were also obtained in healthy volunteers [46] and showed similar plasma concentrations, T_{max} (time to maximal plasma concentration), C_{max}, and terminal half-life (11.8–14.4 h) at day 1 (i.e. after a single dose) and day 10 (steady-state) of treatment. In this study, plasma DPP-4 activity was inhibited by more than 80% over 24 h at 50 mg and higher doses. GLP-1 concentrations were increased by approximately 2-fold by sitagliptin. In obese, non-diabetic subjects, sitagliptin 200 mg bid was well tolerated and led to approximately

Table 1
Gliptins in development and licensed.

Compound	Company	Status
Sitagliptin (MK-0431)	Merck	Launched 2006
Vildagliptin (LAF-237)	Novartis	Launched 2008
Saxagliptin	Bristol-Myers Squibb and Astra Zeneca	Launched 2009; recently approved in Europe for the treatment of T2D with moderate to severe renal insufficiency or mild hepatic insufficiency (2011)
Alogliptin (SYR-322)	Takeda	Launched in Japan
Linagliptin (BI-1356)	Boehringer-Ingelheim	Launched
Dutogliptin (PHX1149)	Phenomix Pharmaceuticals	Phase III
Teneligliptin (MP-513)	Mitsubishi Tanabe Pharma Corp	Phase III, filled application for Japan (Sept. 2011)
SYR472	Takeda	Phase III
KRP104	Kyorin	Phase II
LC15-0444	LG Life Sciences	Phase II
Melogliptin (GRC8200)	Glenmark	Phase II

90% inhibition of plasma DPP-4 activity, increased GLP-1 levels by 2.7-fold, and decreased post-oral glucose tolerance test glucose excursion by 35% compared to placebo [47] (Fig. 3).

Vildagliptin is also well (85%) and rapidly absorbed (within 1–2 h) [48]. Vildagliptin is quickly cleared from plasma, with a half-life of 1.5–4.5 h, thus demanding higher dosing frequency (twice daily vs once daily for other gliptins). PD–PK relationships have been studied in a cross-over, placebo-controlled study in type 2 diabetic patients using doses ranging from 10 and 25 to 100 mg twice a day, for 28 days [49]. More than 90% inhibition of DPP-4 activity was observed at all doses, and more than 80% 12 h post-dosing [50].

Saxagliptin displays a good bioavailability (67%) and is also a potent selective long-acting DPP-4 inhibitor administered usually at a dose of 5 mg/day once a day [51]. As vildagliptin, it is cleared rapidly from the plasma with a life of 2.5 h, and between 3 and 7 h for its major 5-hydroxy saxagliptin metabolite (BMS-510849), also a reversible inhibitor of DPP-4 but 2-fold less potent than the parent molecule. However, it is administered once daily, based on the reasoning that saxagliptin, as vildagliptin, forms a covalent, yet reversible, complex with the enzyme, which has been suggested to confer an extended activity, whereas sitagliptin, alogliptin and linagliptin form non-covalent bounds.

The PK–PD relationship of various doses (25, 100 or 400 mg) of alogliptin was studied in type 2 diabetic patients over 14 days [52]. A potent inhibition of plasma DPP-4 activity (82–97%) was observed at 24 h after administration of the last dose [53]. Alogliptin is usually used at 25 mg once a day.

Linagliptin is generally used at a dose of 25 mg once a day. It inhibits DPP-4 in vitro with a lower IC50 ∼ 1 nM compared to other gliptins. Linagliptin has been administered to healthy volunteers at different doses (up to 600 mg). It is well tolerated, with a low renal excretion and a terminal half-life around 180 h [54]. Single doses of 2.5 mg and 5 mg inhibited DPP-4 activity by 72.7% and 86.1%.

1.3.1. Potency and duration of inhibition

As outlined above, although some differences exist with regards to their chemical structures and pharmacodynamics-kinetics, when administered at therapeutic doses (from 5 to 100 mg) and dosing frequencies (once/twice a day), they all potently inhibit plasma DPP-4 activity (measured ex vivo) by 70–90% at 24 h post-dosing. Indeed, a single dose of sitagliptin (100 mg) inhibited plasma DPP-4 activity by ≥80% over a 24-h period [46], while the same dose of vildagliptin inhibited by more than 80% DPP-4 activity 12 h post-dosing [50]. Similar results were obtained in healthy and type 2 diabetic patients, with 25 mg alogliptin or 5 mg linagliptin, with more than 80% inhibition over 24 h [53–55]. Thus, all DPP-4 inhibitors exert potent and sustained DPP-4 inhibition at therapeutic dosing.

1.3.2. Metabolism and excretion

Sitagliptin is mainly (74%) eliminated unmodified via the kidney in a dosage-independent manner, and renal insufficiency may cause an increase in circulating levels [56,57] requiring different dosing in these patients. A single dose of 50 or 25 mg sitagliptin has been administered daily to type 2 diabetic patients with renal insufficiency for 54 weeks [58]. A reduction of HbA1c levels by 0.7% has been observed and adverse events were not increased. Sitagliptin gives rise through the action of hepatic CYP450 to 6 metabolites, 3 being active [57]. As sitagliptin, alogliptin is mainly excreted unchanged in the urine [53]. In contrast, linagliptin is primarily excreted via the bile, and renal impairment has only a minor effect on linagliptin pharmacokinetics. Thus, there will be no need for adjusting the linagliptin dose in renally impaired patients with T2D [59]. By contrast, vildagliptin is mainly (>50%) hydrolysed by P450 cytochromes to one major pharmacologically inactive compound which is excreted in the urine. Hence, dose adjustment may apply in renal or hepatic insufficiency. Saxagliptin is metabolized in the liver via P450 cytochromes to an active compound which is also a competitive reversible DPP-4 inhibitor. Both this compound and the parent saxagliptin are cleared by the kidney. However, hepatic insufficiency does not seem to alter the pharmacokinetics of saxagliptin [60].

1.3.3. Selectivity

DPP-4 belongs to a large family of structurally related prolyl-peptidases which includes also DPP-8 and DPP-9. Lankas et al. have shown that DPP-8/9 inhibition in vivo in rats leads to alopecia, thrombocytopenia, reticulocytopenia, enlarged spleen, multiorgan histopathological changes, and mortality [61]. Non- or partial selectivity of DPP-4 inhibitors could therefore be of clinical importance although a class effect is very unlikely because of the differences in the chemical structure of the different DPP-4 inhibitors. Hence, molecules thought to be specifically DPP-4-targeted may in fact inhibit other enzymes of this family and its selectivity should be carefully examined. Sitagliptin, alogliptin and linagliptin are highly selective of DPP-4, whereas vildagliptin appears less selective. However, in mice and rats, chronic administration of vildagliptin at doses allowing DPP8/9 inhibition did not result in organ toxicity [62].

1.4. DPP-4 inhibitors in clinical trials

Although structurally different, all DPP-4 inhibitors efficiently lower fasting and post-prandial hyperglycaemia and reduce HbA1c levels by 0.7–1% as shown in numerous phase II and phase III trials. They also improve β-cell function in short-term studies as attested by the HOMA-B index and the decreased pro-insulin/insulin ratio.

Sitagliptin

Vildagliptin

Saxagliptin

Alogliptin

Linagliptin

Fig. 3. Structure of the different approved DPP-4 inhibitors.

1.4.1. Sitagliptin

Sitagliptin has been evaluated in several phase III trials as monotherapy or combination therapy. As monotherapy, in a placebo-controlled, double-blind, 24 weeks study, sitagliptin 100 mg and 200 mg led to a reduction in HbA1c (−0.79 and −0.94%, respectively) and fasting glucose (−17.1 mg/dl and −21.3 mg/dl, respectively) levels, and lower post-prandial glucose in a meal tolerance test [63]. A greater reduction of HbA1c was achieved in patients with baseline HbA1c ≥ 9% (placebo-subtracted reductions of −1.52 and −1.50% for the 100- and 200-mg treatment groups, respectively). At 24 weeks, the percentage of patients achieving HbA1c < 7% was 41% with 100 mg and 45% with 200 mg vs 17% for placebo. In this study, sitagliptin also improved the HOMA-B index without clinically relevant hypoglycaemic episodes and with a small but significant weight loss compared to placebo.

In a double-blind, randomized study, sitagliptin 100 mg/d alone or in combination with 2 g/d metformin during 24 weeks reduced HbA1c levels by 0.83% and 2.07% vs placebo, respectively, demonstrating an additive effect [64]. Adverse effects were similar to those with metformin alone. In another study, sitagliptin 100 mg has been given in association with metformin vs metformin alone, for 24 weeks. Sitagliptin reduced HbA1c levels by an additional 0.65% [65]. Fasting blood glucose was also reduced by 25.4 mg/dl, HOMA-B was improved and body weight remained unchanged. A small but significant decrease in plasma cholesterol (total- and non-HDL-cholesterol) and triglycerides was also observed with sitagliptin 100 mg but the between-group (placebo-subtracted) differences were not significant.

Sitagliptin (100 mg once daily) in association with pioglitazone 30 or 45 mg/d was evaluated in a 24-week study. It reduced HbA1c levels by 0.85% (baseline HbA1c = 8.1%), fasting blood glucose by 16.7 mg/dl, and after 24 weeks 45% of the patients had HbA1c less than 7% vs only 23% taking pioglitazone alone [66].

Sitagliptin was also evaluated for 52 weeks in a non-inferiority trial compared with a sulphonylurea (glipizide: 5–20 mg/d) in diabetic patients with inadequate control of HbA1c by metformin alone [67]. Sitagliptin was proven non-inferior on HbA1c (−0.67% at 52w) and glucose levels, with significantly less hypoglycaemic episodes and a gradual decrease in body weight compared to glipizide.

Similarly, in another study comparing the addition of sitagliptin or glipizide on on-going metformin therapy during 2 years, sitagliptin reduced HbA1c levels by −0.54% compared to −0.51% with glipizide and the percentage of patients with HbA1c levels <7% was 63% and 59%, respectively [68]. Sitagliptin was associated with weight loss (−1.6 kg) and a lower incidence of hypoglycaemia.

In a recent head-to-head comparison of sitagliptin vs liraglutide, a GLP-1 analog, in patients with inadequate glycaemic control on metformin (mean HbA1c 8.5% at baseline) [69], 100 mg sitagliptin for 26 weeks reduced HbA1c levels by 0.9%, whereas 1.2 mg and 1.8 mg liraglutide led to a significantly greater reduction (−1.24% and −1.50%, respectively). In addition, mean weight loss was greater with liraglutide compared to sitagliptin, whereas nausea was more common with liraglutide than with sitagliptin.

1.4.2. Vildagliptin

Used as a monotherapy for 24 weeks in a double-blind, placebo-controlled study in drug-naïve diabetic patients, vildagliptin (50 mg/d, 50 mg twice a day, or 100 mg qd) significantly reduced HbA1c by 0.5%, 0.7% and 0.9%, respectively, and reduced fasting glucose levels without change in body weight and the incidence of adverse events [70].

Vildagliptin 50 mg once or twice daily in association with metformin for 24 weeks was administered to diabetic patients with baseline HbA1c levels ~8.4%. Vildagliptin 50 and 100 mg reduced HbA1c by −0.7 and −1.1%, respectively. Fasting (−14 and −31 mg/dl) and post-prandial glucose (−34 and −41 mg/dl) was also decreased [71]. In association with pioglitazone (45 mg daily) in diabetic patients with inadequate glycaemic control on prior

monotherapy, vildagliptin (50 mg once or twice daily for 24 weeks) resulted in a decrease of HbA1c levels by −0.8 and −1%, fasting glucose levels by −14.4 and −19.8 mg/dl, and reduced post-prandial glucose [72]. In both studies, no change in body weight was observed, and vildagliptin was well tolerated (the incidence of hypoglycaemia and other adverse effects was not increased).

Vildagliptin 50 mg twice daily vs sulphonylurea (glimepiride) was administered for 52 weeks in patients receiving metformin and displaying inadequate glycaemic control [73]. Vildagliptin treatment reduced HbA1c and fasting glucose levels by −0.44% and −18 mg/dl and was non-inferior compared to glimepiride (mean dose: 4.5 mg/d). The incidence of hypoglycaemic episodes was significantly reduced in the vildagliptin arm compared to the sulphonylurea treated group.

1.4.3. Linagliptin

Linagliptin was also evaluated as monotherapy or add-on therapy and has shown clinically meaningful improvement of glycaemic control in type 2 diabetes. Linagliptin was given as monotherapy, 5 mg once daily achieving a concentration ≥6.4 nM leading to a median >82% DPP-4 inhibition, during 24 weeks in drug-naïve patients or patients receiving oral antidiabetic agents (other than TZDs) prior to a 6-week wash-out period [74]. In this multicentre, randomized, placebo-controlled, phase III trial, linagliptin improved glycaemic control (HbA1c −0.69% from baseline, −1.01% in the patients with a baseline HbA1c ≥9%). The percentage of patients who achieved HbA1c < 7% was 25.2% with linagliptin vs 11.6% in the placebo group. Fasting and 2 h post-prandial glucose were significantly reduced in the linagliptin arm compared to placebo (−1.3 mM [23 mg/dl] vs placebo and −3.2 mM [58 mg/dl] vs placebo, respectively). Glucose excursion after a test meal was also significantly reduced. In addition, an enhancement of β-cell function was observed (differences were seen in the proinsulin/insulin ratio, the HOMA-B index and the disposition index). Linagliptin was well tolerated and the safety profile was comparable to the placebo group (no drug-related serious event) and hypoglycaemic episodes were not increased compared to the placebo group. There was no increase of body weight.

The efficacy and safety of linagliptin (5 mg once daily) in combination with metformin during 24 weeks was also evaluated in type 2 diabetic patients in a randomized, placebo-controlled, double-blind, multicentre study [75]. Linagliptin led to a significant reduction in HbA1c (−0.5% from baseline) and fasting and post-prandial glucose. The risk of hypoglycaemic episode was not increased and linagliptin was weight neutral. As mentioned above, linagliptin is mainly excreted unchanged in the urine and can thus be used in patients with severe renal insufficiency [76].

Linagliptin (5 mg once daily) has proven non-inferior to sitagliptin (100 mg once daily) in T2D patients in a randomized, double-blind, placebo-controlled study assessing fasting and 24-h plasma glucose changes from baseline as well as plasma GLP-1 AUC (0–2 h) and glucose AUC (0–3 h) from baseline (http://clinical-trials.gov/, NCT00716092).

1.4.4. Alogliptin

Clinical evidence also supports the efficacy of alogliptin. Used as a monotherapy in a double-blind placebo-controlled study, alogliptin 12.5 and 25 mg once daily resulted in a significant reduction of HbA1c by 0.6%, and was weight neutral [77].

Several studies showed that alogliptin in combination with other oral antidiabetic agents also improves glycaemic control. In association with metformin in type 2 diabetic patients with baseline HbA1c from 7 to 10%, 12.5 and 25 mg alogliptin once daily for 26 weeks significantly reduced HbA1c and fasting blood glucose by an additional −0.6% and −17 mg/dl, respectively, over placebo [78].

In a randomized, double-blind trial, the administration of 12.5 and 25 mg alogliptin for 26 weeks in patients inadequately controlled by the sulphonylurea glyburide (mean baseline HbA1c 8.1%) led to a further reduction of HbA1c levels by 0.53 and 0.39%, and fasting glucose by −8.4 and −4.7 mg/dl [79].

Used with insulin, alogliptin 12.5 and 25 mg for 26 weeks improved glycaemic control as Hb1Ac was decreased by 0.63% and 0.71%, respectively [80].

1.4.5. Saxagliptin

Saxagliptin also improves glycaemic control and is well-tolerated. As monotherapy, saxagliptin 2.5, 5, 10, 20 and 40 mg once a day reduced HbA1c levels by 0.45–0.63% vs placebo and was neutral on body weight [81,82]. In another study, saxagliptin 2.5, 5 and 20 mg daily for 24 weeks led to a reduction of HbA1c of 0.43%, 0.46% and 0.54%, respectively [81,82].

Saxagliptin vs placebo added to either metformin, a TZD (rosiglitazone or pioglitazone) or glyburide for 24 weeks resulted in significant reductions in HbA1c (−0.69%, −0.94% and −0.64% at 5 mg) [83–85]. Fasting glucose was also reduced. The incidence of hypoglycaemia and other adverse events was not different from placebo in either three studies. In a randomized, double-blind, placebo-controlled study, saxagliptin was given for 12 weeks at 2.5 mg once daily to patients with renal impairment and inadequately controlled type 2 diabetes (baseline HbA1c 7–11%) [86]. In this study, saxagliptin lowered HbA1c by 0.42% over placebo, and achieved greater HbA1c reduction than placebo in a subset of patients with moderate (−0.64% vs −0.05%) and severe (−0.95% vs −0.50%) renal insufficiency.

Saxagliptin 5 mg once daily and sitagliptin 100 mg once daily were compared in a head to head, 18-week, double-blind, non-inferiority trial in patients on metformin with inadequately controlled glycaemia [87]. The mean changes in HbA1c in the saxagliptin and sitagliptin groups were −0.52 and −0.62%, respectively. There was no between-group difference, demonstrating non-inferiority of saxagliptin vs sitagliptin. Both treatments were equally tolerated.

1.5. Adverse effects

DPP-4 inhibitors are generally well-tolerated, and no increase in adverse events was noted compared to placebo or other comparatives, but again slight differences may exist between the different molecules of this class. DPP-4 is also present on the cell membrane of T lymphocytes known as CD26. In these cells, it acts by activating intracellular signalling pathways to simulate T-cell proliferation. In pre-clinical models, DPP-4-deficiency results in modest abnormalities in immune response, decreased CD4+ T-cell number, and reduced production of interleukin (IL)-4 while IL-10 was increased [88,89]. However, the peptidase activity of DPP-4 has not been associated to immune function. DPP-4 inhibitors did not affect immune function in rats and dogs [61]. The effect of sitagliptin was also examined in type 1 diabetes where it was shown to reduce the effect of autoimmunity on islet graft survival linked to decreased T-cell migration [90]. In the same line, alogliptin was shown to suppress LPS-induced TLR-4 signalling [91]. Saxagliptin administration led also to a modest reduction in lymphocyte count within the normal range [81]. DPP-4 inhibition may also affect human progenitor cell and haematopoietic stem cell migration [92]. To date, no adverse events related to immunological effects have been reported in humans but additional long-term trials are needed before to conclude on their safety profile with regards to immunological issues.

Some infections of the urinary tract and of the upper respiratory tract (nasopharyngitis) were reported to be slightly increased with

Table 2
Ongoing trials investigating the effects of DPP-4 inhibitors on cardiovascular disease outcomes.

Trial	Intervention and duration	Inclusion and estimated nb of patients	Primary endpoint	Estimated completion date/status
TECOS (Phase III) NCT00790205[*]	Sitagliptin vs placebo (up to 5 years)	14,000 subjects with T2D and inadequate glycaemic control and history of CVD, >50 y	CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization	Dec 2014/Recruiting
CAROLINA (Phase III) NCT01243424	Linagliptin vs glimepiride 400 weeks (7.5 years)	6000 T2D patients	CV death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina pectoris at Week 400 (or FinalVisit)	Sept 2018/Recruiting
SAVOR-TIMI 53 (Phase IV) NCT01107886	Saxagliptin vs placebo (5 years)	16,500 T2D patients	CV death, non-fatal MI or non-fatal ischaemic stroke	April 2014/Recruiting
EXAMINE (Phase III) NCT00968708	Alogliptin vs placebo (4.7 years)	5400 T2D patients with acute coronary syndrome	CV, nonfatal MI and nonfatal stroke	Dec 2014/Recruiting

[*] clinicaltrials.gov identifier.

the use of sitagliptin and vildagliptin, but this was not confirmed in later studies [93].

As mentioned above, several hormones and peptides harbouring an alanine or a proline at position 2 are degraded by DPP-4 in in vitro systems [43], although only a few were identified as endogenous physiological substrates. These include the chemokines SDF1α and β, GLP-2 and the vasodilatator substance P. DPP-4 inhibitors are considered as safe therapies, and no serious adverse events have been reported. Nevertheless as with all new drug classes, long-term follow up is required to evaluate potential safety issues.

1.6. DPP4 inhibitors and cardiovascular risk

Numerous studies have evidenced a role for GLP-1 in the cardiovascular system. On the one hand, continuous IV administration of GLP-1 in cardiac insufficiency and myocardial infarction improves cardiac function by increasing left ventricular ejection fraction [94]. Administration of the DPP-4-resistant GLP-1 analog exendin-4 to apoE-deficient mice, which spontaneously develop atherosclerosis, diminished atherosclerotic lesion size and monocyte/macrophage recruitment to the vascular wall independent of changes in plasma lipid levels or glucose tolerance [95]. On the other hand, deletion of the GLP-1 receptor in mice results in increased left ventricular diastolic pressure, decreased left ventricle (LV) contractility and increased LV thickness [96]. In humans, GLP-1 administration increased left ventricular ejection fraction and improved the resistance to exercise in diabetic and non-diabetic patients with cardiac insufficiency [97], suggestive of a potential cardioprotective effect of GLP-1. In the same line, GLP-1 infusion lowered arrhythmia in patients with coronary artery bypass grafting [98], while retrospective database analysis suggested that administration of exenatide may diminish the relative risk of CVD in type 2 diabetic patients [99]. By contrast, 48-h GLP-1 infusion had no major cardiovascular effects in patients with congestive heart failure [100].

A recent study conducted in 14 patients with coronary artery disease indicated that a single administration of 100 mg sitagliptin increases ejection fraction and improves contractile function on ischaemic segments [101]. It is noteworthy that not all effects are necessarily dependent on DPP-4 as sitagliptin was shown to slightly improve recovery from ischaemia-reperfusion in isolated hearts from DPP-4 deficient as well as wild-type mice [102]. In addition, sitagliptin was shown to reduce diastolic blood pressure and heart rate with a similar extent than liraglutide [69]. A meta-analysis has suggested a potential reduction of cardiovascular events with saxagliptin [103]. A meta-analysis of 29 placebo-controlled and 11 active comparator, randomized trials with DPP-4 inhibitors (sitagliptin and vildagliptin) also found a reduction in the risk of cardiovascular events (odd ratio = 0.76 vs control

groups) [104]. Thus, evidence so far indicates that gliptins do not adversely affect the risk of cardiovascular events and animal studies suggest potential protective effects. However, prospective trials investigating the effects of DPP-4 inhibitors on cardiovascular outcomes are ongoing (Table 2) and the results eagerly awaited. TECOS (http://clinicaltrials.gov/, NCT00790205) is a randomized, placebo-controlled clinical trial designed to assess the cardiovascular outcome of long-term (up to 5 years) treatment with sitagliptin in an estimated number of 14,000 patients with T2D (HbA1c between 6.5% and 8.0%) and a history of cardiovascular disease. Primary end-points are defined as CV-related death, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina requiring hospitalization ([105] and http://clinicaltrials.gov/). The cardiovascular safety of linagliptin will be tested in a randomized, double-blind study in 6000 patients with T2D and at elevated cardiovascular risk. Linagliptin will be compared against glimepiride (CAROLINA study) [106]. The primary outcome is defined as the time to the first occurrence of any of the following events: CV death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina pectoris (http://clinicaltrials.gov/, NCT01243424). SAVOR-TIMI 53 (NCT01107886) is a randomized, double-blind, placebo-controlled phase IV trial evaluating the effect of saxagliptin on the incidence of cardiovascular death, non-fatal MI or non-fatal ischaemic stroke in 16,500 patients with T2D. Finally, EXAMINE (NCT00968708) is a randomized, double-blind, placebo-controlled study that will evaluate cardiovascular outcomes upon treatment with alogliptin in subjects with T2D and acute coronary syndrome (acute MI or unstable angina) [107]. In addition, the effects of 52 weeks vildagliptin treatment on LV function will be tested in patients with T2D and congestive heart failure (NCT00894868) in a randomized, double-blind, placebo-controlled phase IV trial (estimated completion date Jan. 2013).

1.7. Conclusion

DPP-4 inhibitors are a novel class of orally available molecules for the treatment of type 2 diabetes. Although structurally different, they share a common mechanism of action by extending the half-life of endogenous GLP-1 thus prolonging its actions, they potently reduce blood glucose levels and lower HbA1c by up to 1%. They are generally well tolerated and safe. Because GLP-1 is secreted in a glucose-dependent manner, DPP-4 inhibitors, which prolong its half-life, are not associated with an increased risk of hypoglycaemic episodes.

Financial support

Conflict of interest

BS has been advisor of Genfit, Merck, Roche, Daiichi-Sankyo. BC has received fees for consultancy, speaking, travel or accommodation from AstraZeneca, Bristol Myers Squibb, Eli Lilly & Co, Genfit, Merck & Co Inc, Novartis, Novo Nordisk, Sanofi and Servier.

References

[1] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65.

[2] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577–89.

[3] Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2477–80.

[4] Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986;63:492–8.

[5] Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357–66.

[6] Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973;37:826–8.

[7] Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159–66.

[8] Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983;304:368–71.

[9] Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986;119:1467–75.

[10] Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300–4.

[11] Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616–9.

[12] Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987;84:3434–8.

[13] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57.

[14] Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 1989;38:338–42.

[15] Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 1998;47:632–9.

[16] Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology 2007;133: 1796–805.

[17] McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 2007;293:E1746–55.

[18] Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999;96:14843–7.

[19] Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738–42.

[20] Hansotia T, Baggio LL, Delmeire D, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326–35.

[21] Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52.

[22] Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609–13.

[23] Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59:1117–25.

[24] Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717–23.

[25] Rask E, Olsson T, Soderberg S, et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001;24:1640–5.

[26] Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678–87.

[27] Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38:916–9.

[28] Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–8.

[29] Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126–31.

[30] Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575–81.

[31] Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:6825–30.

[32] Marguet D, Baggio L, Kobayashi T, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874–9.

[33] Pospisilik JA, Stafford SG, Demuth HU, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002;51:943–50.

[34] Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741–50.

[35] Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998;47: 1253–8.

[36] Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 2002;51:2677–83.

[37] Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 2007;143:97–103.

[38] Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007;56:8–15.

[39] Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008;57:1331–9.

[40] Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 2009;137:2146–57.

[41] Mu J, Petrov A, Eiermann GJ, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009;623:148–54.

[42] Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695–704.

[43] Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48:616–20.

[44] Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007;56: 3006–13.

[45] Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675–88.

[46] Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55–72.

[47] Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876–86.

[48] Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774–89.

[49] He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46:577–88.

[50] He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633–41.

[51] Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:5025–37.

[52] Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297–300.

[53] Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008;30:499–512.

[54] Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 2008;48:1171–8.

[55] Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009;11:786–94.

[56] Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862–4.

[57] Vincent SH, Reed JR, Bergman AJ, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533–8.

[58] Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545–55.

[59] Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab 2011;13:939–46.

[60] Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009;23:487–98.

[61] Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988–94.

[62] Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057–61.

[63] Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7.

[64] Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87.

[65] Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43.

[66] Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–68.

[67] Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205.

[68] Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562–76.

[69] Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447–56.

[70] Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132–8.

[71] Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890–5.

[72] Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–74.

[73] Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157–66.

[74] Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258–67.

[75] Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65–74.

[76] Sloan L, Newman J, Sauce C, von Eynatten M, Patel S, Safety Woerle HJ. Efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes 2011;60:A114.

[77] DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315–7.

[78] Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46–55.

[79] Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167–76.

[80] Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009;11:1145–52.

[81] Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376–86.

[82] Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009;25:2401–11.

[83] DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–55.

[84] Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009;94:4810–9.

[85] Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009;63:1395–406.

[86] Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011;13:523–32.

[87] Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540–9.

[88] El Yacoubi M, Vaugeois JM, Marguet D, et al. Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity. Behav Brain Res 2006;171:279–85.

[89] Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519–27.

[90] Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 2009;58:641–51.

[91] Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang YDPP-4. (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010;213:429–35.

[92] Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004;305:1000–3.

[93] Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009;32(Suppl. 2):S223–31.

[94] Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962–5.

[95] Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030–7.

[96] Gros R, You X, Baggio LL, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003;144:2242–52.

[97] Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694–9.

[98] Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824–9.

[99] Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90–5.

[100] Halbirk M, Norrelund H, Moller N, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298:H1096–102.

[101] Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and

mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195–201.

[102] Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063–73.

[103] Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16–27.

[104] Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010;20:224–35.

[105] Bethel MA, Green J, Califf R, Holman R. Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). In: ADA; 2009. Poster 2152-PO.

[106] Rosenstock J, Marx N, Kahn SE, et al. Rationale and design of the CAROLINA trial: an active comparator CARdiOvascular Outcome Study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk. Diabetes 2011;60:A303.

[107] White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J 2011;162:620–6.